Biological markers in schizophrenia

An update

Vishal Madaan, Durga Prasad Bestha, Venkata Kolli

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Biological markers are quantitative measures that allow clinicians to diagnose and assess the disease process, monitor response to treatment and may, to some extent, assist with prognostic assessments (1). Biological markers can modify the way clinicians approach, treat and care for patients. This has significant diagnostic and treatment-related implications, especially for chronic disabling disorders with complex etiopathogenesis, such as schizophrenia. Years of research have yielded a variety of relatively consistent findings in different domains including neuroanatomy, functional and molecular neuroimaging, neurophysiology, genetics and biochemistry. These attributes can complement clinical findings with improved diagnostic validity, and to some extent, assist the clinician in early initiation of efficacious treatment and predicting prognosis. On the contrary, many of these potential biological markers may require expensive testing and enhanced technological expertise. Considering the issues with sensitivity and specificity and an overlap with other neuropsychiatric disorders, their role in routine clinical care continues to be ambiguous.

Original languageEnglish (US)
Pages (from-to)661-669
Number of pages9
JournalDrugs of Today
Volume46
Issue number9
DOIs
StatePublished - Sep 1 2010

Fingerprint

Schizophrenia
Biomarkers
Neuroanatomy
Neurophysiology
Functional Neuroimaging
Biochemistry
Patient Care
Therapeutics
Sensitivity and Specificity
Research

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Biological markers in schizophrenia : An update. / Madaan, Vishal; Bestha, Durga Prasad; Kolli, Venkata.

In: Drugs of Today, Vol. 46, No. 9, 01.09.2010, p. 661-669.

Research output: Contribution to journalReview article

Madaan, Vishal ; Bestha, Durga Prasad ; Kolli, Venkata. / Biological markers in schizophrenia : An update. In: Drugs of Today. 2010 ; Vol. 46, No. 9. pp. 661-669.
@article{26b13b02197643ef9866d4d27734b4bc,
title = "Biological markers in schizophrenia: An update",
abstract = "Biological markers are quantitative measures that allow clinicians to diagnose and assess the disease process, monitor response to treatment and may, to some extent, assist with prognostic assessments (1). Biological markers can modify the way clinicians approach, treat and care for patients. This has significant diagnostic and treatment-related implications, especially for chronic disabling disorders with complex etiopathogenesis, such as schizophrenia. Years of research have yielded a variety of relatively consistent findings in different domains including neuroanatomy, functional and molecular neuroimaging, neurophysiology, genetics and biochemistry. These attributes can complement clinical findings with improved diagnostic validity, and to some extent, assist the clinician in early initiation of efficacious treatment and predicting prognosis. On the contrary, many of these potential biological markers may require expensive testing and enhanced technological expertise. Considering the issues with sensitivity and specificity and an overlap with other neuropsychiatric disorders, their role in routine clinical care continues to be ambiguous.",
author = "Vishal Madaan and Bestha, {Durga Prasad} and Venkata Kolli",
year = "2010",
month = "9",
day = "1",
doi = "10.1358/dot.2010.46.9.1485923",
language = "English (US)",
volume = "46",
pages = "661--669",
journal = "Drugs of Today",
issn = "0025-7656",
publisher = "Prous Science",
number = "9",

}

TY - JOUR

T1 - Biological markers in schizophrenia

T2 - An update

AU - Madaan, Vishal

AU - Bestha, Durga Prasad

AU - Kolli, Venkata

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Biological markers are quantitative measures that allow clinicians to diagnose and assess the disease process, monitor response to treatment and may, to some extent, assist with prognostic assessments (1). Biological markers can modify the way clinicians approach, treat and care for patients. This has significant diagnostic and treatment-related implications, especially for chronic disabling disorders with complex etiopathogenesis, such as schizophrenia. Years of research have yielded a variety of relatively consistent findings in different domains including neuroanatomy, functional and molecular neuroimaging, neurophysiology, genetics and biochemistry. These attributes can complement clinical findings with improved diagnostic validity, and to some extent, assist the clinician in early initiation of efficacious treatment and predicting prognosis. On the contrary, many of these potential biological markers may require expensive testing and enhanced technological expertise. Considering the issues with sensitivity and specificity and an overlap with other neuropsychiatric disorders, their role in routine clinical care continues to be ambiguous.

AB - Biological markers are quantitative measures that allow clinicians to diagnose and assess the disease process, monitor response to treatment and may, to some extent, assist with prognostic assessments (1). Biological markers can modify the way clinicians approach, treat and care for patients. This has significant diagnostic and treatment-related implications, especially for chronic disabling disorders with complex etiopathogenesis, such as schizophrenia. Years of research have yielded a variety of relatively consistent findings in different domains including neuroanatomy, functional and molecular neuroimaging, neurophysiology, genetics and biochemistry. These attributes can complement clinical findings with improved diagnostic validity, and to some extent, assist the clinician in early initiation of efficacious treatment and predicting prognosis. On the contrary, many of these potential biological markers may require expensive testing and enhanced technological expertise. Considering the issues with sensitivity and specificity and an overlap with other neuropsychiatric disorders, their role in routine clinical care continues to be ambiguous.

UR - http://www.scopus.com/inward/record.url?scp=79955896410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955896410&partnerID=8YFLogxK

U2 - 10.1358/dot.2010.46.9.1485923

DO - 10.1358/dot.2010.46.9.1485923

M3 - Review article

VL - 46

SP - 661

EP - 669

JO - Drugs of Today

JF - Drugs of Today

SN - 0025-7656

IS - 9

ER -